C-FOXP3+E-Cadherin− tumor epithelial cells can rejuvenate tumor angiogenesis in a VEGF-independent manner, elucidating potential resistance mechanisms to anti-VEGF therapy in patients with PDAC. This evidence concerns the gene FOXP3 and neoplasm.